1309832-87-8

Basic information

• Product Name: 1-(4-fluoro-5-nitrophenyl)-1,4-dihydro-5H-tetrazol-5-one
• Synonyms: 1-(4-fluoro-5-nitrophenyl)-1,4-dihydro-5H-tetrazol-5-one
• CAS NO: 1309832-87-8
• Molecular Weight: 225.139
• Mol File: 1309832-87-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-fluoro-5-nitrophenyl)-1,4-dihydro-5H-tetrazol-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluoro-5-nitrophenyl)-1,4-dihydro-5H-tetrazol-5-one(1309832-87-8)
• EPA Substance Registry System: 1-(4-fluoro-5-nitrophenyl)-1,4-dihydro-5H-tetrazol-5-one(1309832-87-8)

Safety Data

• Hazardous Substances Data: 1309832-87-8(Hazardous Substances Data)

Upstream product

• 4648-54-8 trimethylsilylazide 
• 400-94-2 4-fluoro-3-nitrobenzoyl chloride 

Downstream Products

• 1309832-88-9 1-(4-fluoro-3-nitrophenyl)-4-methyl-1H-tetrazol-5(4H)-one 
• 1309832-89-0 1-(3-amino-4-fluorophenyl)-4-methyl-1H-tetrazol-5(4H)-one 
• 1309832-90-3 1-(4-fluoro-3-(5-fluoro-4-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidin-2-ylamino)phenyl)-4-methyl-1H-tetrazol-5(4H)-one 

Relevant articles and documents

A one-pot synthesis of tetrazolones from acid chlorides: Understanding functional group compatibility, and application to the late-stage functionalization of marketed drugs

A one-pot and scalable synthesis of tetrazolones (tetrazol-5-ones) from acid chlorides using azidotrimethylsilane is presented. The reaction tolerates many functional groups and can furnish aryl-, heteroaryl-, alkenyl-, or alkyl-substituted tetrazolone products in moderate to excellent yield (14-94%). No reduction in yield was observed when the reaction was undertaken on a larger-scale (20-36 g). The method could be used for the late-stage functionalization of pharmaceuticals, to provide tetrazolone congeners of the marketed drugs aspirin, indomethacin, probenecid, telmisartan, bexarotene, niacin (vitamin B3), and the active metabolite of the recently-launched immuno-modulatory agent, BG-12 (Tecfidera). The ability of a tetrazolone group to serve as a bioisostere of a carboxylic acid, and to improve drug pharmacokinetic profiles is also highlighted.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.